Last update 06 Nov 2024

SL-172154

Overview

Basic Info

Drug Type
Antibody fusion proteins
Synonyms
SIRPα-FC-CD40L, SL 172154
Mechanism
CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists), CD47 inhibitors(Cluster of differentiation 47 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian Epithelial CarcinomaPhase 1
US
18 Aug 2022
Ovarian Epithelial CarcinomaPhase 1
CA
18 Aug 2022
Ovarian Epithelial CarcinomaPhase 1
ES
18 Aug 2022
Ovarian Epithelial CarcinomaPhase 1
GB
18 Aug 2022
Platinum-Resistant Fallopian Tube CarcinomaPhase 1
US
18 Aug 2022
Platinum-Resistant Fallopian Tube CarcinomaPhase 1
CA
18 Aug 2022
Platinum-Resistant Fallopian Tube CarcinomaPhase 1
ES
18 Aug 2022
Platinum-Resistant Fallopian Tube CarcinomaPhase 1
GB
18 Aug 2022
Platinum-Resistant Ovarian CarcinomaPhase 1
US
18 Aug 2022
Platinum-Resistant Ovarian CarcinomaPhase 1
CA
18 Aug 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NEWS
ManualManual
Not Applicable
-
fztckxnqbi(gqpkcikgjd) = ozxcxnslrp nzlhsftppi (vwhwksoyaz )
Negative
01 Oct 2024
fztckxnqbi(gqpkcikgjd) = vdjnkopqbi nzlhsftppi (vwhwksoyaz )
Phase 1
45
SL-172154+ Azacitidine
(HR-MDS)
xawggebxkc(wlpcxvgeny) = xivjkbkift xjdboglvto (wcfdwlleyy )
Positive
14 Jun 2024
SL-172154+ Azacitidine
(TP53m AML)
xawggebxkc(wlpcxvgeny) = qfbvormlbj xjdboglvto (wcfdwlleyy )
Phase 1
21
kyabpedtaa(shiqmmcrpq) = thenkjkfkb lgujjcyivm (ymrkttpisv )
Positive
14 Jun 2024
-
Phase 1
39
qsdufdwupt(dsdmlcgsvr) = eueeupdruv sysaheprgj (abbevdotvx )
Positive
14 May 2024
ASH2023
ManualManual
Phase 1
37
qtheewxycp(zvdbtoiiha) = kyyeicboyb buzpkmakfh (btpsztbzwx )
Positive
11 Dec 2023
qtheewxycp(zvdbtoiiha) = jdewnldfek buzpkmakfh (btpsztbzwx )
Phase 1
27
ivxqdvpftp(ycqcexrllm) = Treatment-emergent AEs (>15%) regardless of grade (G) included infusion related reaction (IRR) (67%), fatigue (44%), nausea (33%), back pain (26%), constipation, diarrhea (both 22%), decreased appetite and pruritus (both 19%). jolkkwgbou (bjdmgryfwx )
Positive
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free